Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 5, 2024
Discovery & Translation
New frontiers in extracellular protein degradation
Six papers detail improved ways to degrade cell-surface cancer proteins through the lysosome
BioCentury | Mar 23, 2023
Emerging Company Profile
EpiBiologics tapping two lysosomal degradation mechanisms with $50M
The UCSF spinout is degrading membrane-bound and extracellular targets via bispecific antibody constructs it believes have a manufacturing advantage
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Sep 23, 2022
Discovery & Translation
PROTAC logic continues to evolve
New publications highlight bispecific antibody degraders as a way to eliminate a cell surface target
BioCentury | Jan 21, 2022
Emerging Company Profile
Avilar: Targeted degradation for extracellular proteins
RA Capital-incubated biotech is harnessing a receptor present on liver cells to internalize and degrade extracellular proteins
BioCentury | Nov 19, 2021
Finance
Nov. 18 Quick Takes: RA’s Avilar raises $60M seed for protein degradation tech
Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali
BioCentury | Aug 20, 2021
Product Development
The TAC universe grows beyond PROTACs
Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation
BioCentury | Mar 27, 2021
Translation in Brief
Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more
BioCentury’s roundup of translational news
BioCentury | Aug 22, 2020
Translation in Brief
IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more
BioCentury’s roundup of translational news
BioCentury | Aug 11, 2017
Strategy
The flip-side of immunotherapy
How immuno-oncology targets are spawning new therapies for inflammation
Items per page:
1 - 10 of 11